Skip to Content

'
Brian F. Chapin, MD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2004 Georgetown University School of Medicine, Washington, DC, MD, Medicine
2000 Siena College, Loudonville, NY, BS, Summa Cum Laude, Biology

Postgraduate Training

2010-2012 Clinical Fellowship, Urologic Oncology, UT MD Anderson Cancer Center, Houston, TX
2006-2009 Clinical Residency, Urology, Massachusetts General Hospital, Boston, MA
2005-2006 Clinical Residency, General Surgery, Massachusetts General Hospital, Boston, MA
2004-2005 Clinical Internship, General Surgery, Massachusetts General Hospital, Boston, MA

Board Certifications

3/2014 American Board of Urology

Experience/Service

Administrative Appointments/Responsibilities

Rotation Site Director, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 3/2013-present
Administrative Fellow, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/2011-10/2011
Administrative Chief Resident, Massachusetts General Hospital, Boston, MA, 12/2008-6/2009
Administrative Chief Resident, Children's Hospital Boston, Boston, MA, 7/2008-9/2008

Honors and Awards

2011 Best of Posters AUA/JUA: Post-operative Complications from Cytoreductive Nephrectomy after Pre-surgical Targeted Therapy for Metastatic Renal Cell Carcinoma, AUA
2011 Merit Award. Genitourinary Cancer Symposium (GU ASCO), American Society of Clinical Oncology
2010-2011 American Urologic Association Foundation Research Scholarship, AUA
2007 Harvard Medical School Resident Teaching Award, Massachusetts General Hospital
2007 Partners in Excellence Award, Massachusetts General Hospital
2004 Cum Laude, Georgetown University School of Medicine

Professional Memberships

American Society of Clinical Oncology (ASCO)
Associate Member, 2010-present
American Urological Association (AUA)
Candidate Member, 2006-present
Endourological Society
Member, 2006-present
European Association of Urology (EAU)
Junior International Member, 2010-present
Harris County Medical Society
Member, 2011-present
Sexual Medicine Society of North America (SMSNA)
Candidate Member, 2009-present
Society of Urologic Oncology (SUO)
Candidate Member, 2011-present
South Central Section of the American Urological Association (SCSAUA)
Candidate Member, 2012-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Wirth GJ, Psutka SP, Chapin BF, Wu S, Wu CL, Dahl DM. Midterm Oncological Outcomes of Laparoscopic vs Open Radical Prostatectomy (RP). BJU Int 112(2):190-7, 7/2013. e-Pub 4/19/2013. PMID: 23601185.
2. Chapin BF, Delacroix SE Jr, Culp SH, Nogueras Gonzalez GM, Tannir NM, Jonasch E, Tamboli P, Wood CG. Safety of pre-surgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol 60(5):964-71, 11/2011. PMID: 21621907.
3. Costa NG, Delacroix SE, Sleeper JP, Smith PJ, Youssef RF, Chapin BF, Karam JA, Culp S, Abelb EJ, Brugarolasc J, Raja GV, Sagalowsky AI, Wood CG, Margulis V. The impact of targeted molecular therapies on the level of renal cell carcinoma venous tumor thrombus. Eur Urol 59(6):912-28, 2011. PMID: 21367518.
4. Eisner BH, Feldman AS, Chapin BF, Dretler SP. "Blind coning"--using the stone cone for removal of intramural ureteral calculi. Urology 69(4):773-75, 2007. PMID: 17445670.
5. Oyelese Y, Tchabo JG, Chapin BF, Nair A, Hanson P, McLaren R. Conservative management of uterine rupture diagnosed prenataly on ultrasound. Ultrasound in Medicine 22:977-80, 2003. PMID: 14510271.

Invited Articles

1. Delacroix SE, Chapin BF, Wood CG. The role of lymph node dissection in renal cell carcinoma. Urology Clinics of North America. In Press.
2. Chapin BF, Delacroix SE, Wood CG. Renal cell carcinoma; what the surgeon and treating physician need to know. American Journal of Roentgenology 196(6):1255-62, 6/2011.
3. Chapin BF, Delacroix SE, Wood CG. The role of lymphadenectomy in renal cell carcinoma. International Journal of Clinical Oncology 16(3):186-94, 6/2011.

Editorials

1. Chapin BF, Wood CG. The R.E.N.A.L. nephrometry nomogram: statistically significant, but is it clinically relevant? Eur Urol 60(2):249-51, 8/2011.

Abstracts

1. Chapin, BF, Delacroi SE, et al. Can a Lymph node dissection alter outcomes in metastatic renal cell carcinoma?. AUA Annual Meeting, 2012.
2. Delacroix SE, Chapin BF, Cost N, Karam JA, Culp S, Abel EJ, Gonzalez G, Margulis V, Wood CG. Can contemporary targeted therapies provide clinically meaningful changes in renal cell carcinoma venous tumor thrombi?. Genitourinary Cancers Symposium (GU ASCO) and American Urologic Association, Orlando, Florida, 2011.
3. Delacroix SE, Chapin BF, Cost N, Karam JA, Culp S, Abel EJ, Gonzalez G, Margulis V, Wood CG. Can contemporary targeted therapies provide clinically meaningful changes in renal cell carcinoma venous tumor thrombi?. Southeastern Sectional of the American Urologic Association, 2011.
4. Chapin BF, Delacroix SE, Culp SH, Gonzalez G, Wood CG. Post operative complications from cytoreductive nephrectomy after neoadjuvant targeted therapy for metastatic renal cell carcinoma. Southeastern Sectional of the American Urologic Association, 2011.
5. Chapin BF, Delacroix SE, Culp SH, Gonzalez G, Wood CG. Post operative complications from cytoreductive nephrectomy after pre-surgical targeted therapy for metastatic renal cell carcinoma. American Urologic Association Annual Meeting, 2011.
6. Chapin BF, Delacroix SE, Culp SH, Gonzalez G, Wood CG. Post operative complications from cytoreductive nephrectomy after pre-surgical targeted therapy for metastatic renal cell carcinoma. Genitourinary Cancer Symposium (GU ASCO), 2011.
7. Cost NG, Delacroix SE, Smith P, Youssef RF, Chapin BF, Karam J, Culp SH, Abel EJ, Rak GV, Sagalowsky AI, Wood CG, Margulis V. The impact of targeted molecular therapies on the Level of renal cell carcinoma venous tumor thrombus. Society of Urologic Oncology. 2010, American Urologic Association, Orlando, Florida. 2011, ASCO 2011, J Clin Oncol 29: (suppl; abstr e15002), 2011.
8. 11. Chapin BF, Delacroix SE, Culp SH, Gonzalez G, Wood CG. Timing of cytoreductive nephrectomy does not influence survival in metastatic renal cell carcinoma. American Urologic Association Annual Meeting, 2011.
9. Chapin BF, Feldman AS, Dahl DM. Hydrodissection of the neurovascular bundles in laparoscopic radical prostatectomy: Impact on positive surgical margins. American Urological Association's National Meeting, 2009.
10. Chapin BF, Feldman AS, Psutka SP, Dahl DM. Predictors of post-prostatectomy incontinence: A multivariate analysis. New England Section of the American Urologic Association Annual Meeting, 2009.
11. Chapin BF, Eisner BH, Samir AM, Eswara JR, Hunter SE, Maher MM, Hahn PF, Gervais DA, McGovern FJ, McDougal WS, Mueller PR. Natural history of renal oncocytoma diagnosed by percutaneous biopsy. New England Section of the American Urologic Association, 2008.
12. Chapin BF, Eisner B, Lahey S, Tabatabaei S. KTP laser photovaporization of prostate in patients with large volume prostates. New England Section of the American Urologic Association, 2007.
13. Eswara JR, Eisner BH, Chapin BF, McDougal WS. Long-term changes in renal function after radical and partial nephrectomy. 102nd Annual Meeting. American Urologic Association, Anaheim, California, 2007.

Book Chapters

1. Chapin BF, Delacroix SE, Wood CG. In: Cytoreductive nephrectomy for advanced disease. In: Renal cell cancer: Principles and practice. Lara P and Jonasch E eds. Springer, 2012.

Last updated: 6/27/2014